# Todd E Golde

List of Publications by Year
in descending order



| | | | |
|---|---|---|---|
| 264 papers | 29,535 citations | 5430 85 h-index | 6686 161 g-index |
| 281 all docs | 281 docs citations | 281 times ranked | 32339 citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Alzheimerâ€™s disease and progressive supranuclear palsy share similar transcriptomic changes in distinct brain regions. Journal of Clinical Investigation, 2022, 132, . | 3.9 | 13 |
| 2 | AAVâ€mediated delivery of an antiâ€BACE1 VHH alleviates pathology in an Alzheimer's disease model. EMBO Molecular Medicine, 2022, 14, e09824. | 3.3 | 13 |
| 3 | Intracerebral but Not Peripheral Infection of Live Porphyromonas gingivalis Exacerbates Alzheimerâ€™s Disease Like Amyloid Pathology in APP-TgCRND8 Mice. International Journal of Molecular Sciences, 2022, 23, 3328. | 1.8 | 8 |
| 4 | Alzheimerâ€™s disease â€“ the journey of a healthy brain into organ failure. Molecular Neurodegeneration, 2022, 17, 18. | 4.4 | 41 |
| 5 | Manifestations of Alzheimerâ€™s disease genetic risk in the blood are evident in a multiomic analysis in healthy adults aged 18 to 90. Scientific Reports, 2022, 12, 6117. | 1.6 | 12 |
| 6 | Disease-Modifying Therapies for Alzheimer's Disease: More Questions than Answers. Neurotherapeutics, 2022, 19, 209-227. | 2.1 | 36 |
| 7 | Pathogenic tau recruits wild-type tau into brain inclusions and induces gut degeneration in transgenic SPAM mice. Communications Biology, 2022, 5, 446. | 2.0 | 4 |
| 8 | Soluble brain homogenates from diverse human and mouse sources preferentially seed diffuse AÎ² plaque pathology when injected into newborn mouse hosts.. Free Neuropathology, 2022, 3, . | 2.4 | 2 |
| 9 | Utility of Plasma Neurofilament Light in the 1Florida Alzheimerâ€™s Disease Research Center (ADRC). Journal of Alzheimer's Disease, 2021, 79, 59-70. | 1.2 | 16 |
| 10 | Targeting Notch in oncology: the path forward. Nature Reviews Drug Discovery, 2021, 20, 125-144. | 21.5 | 152 |
| 11 | Novel Alzheimer Disease Risk Loci and Pathways in African American Individuals Using the African Genome Resources Panel. JAMA Neurology, 2021, 78, 102. | 4.5 | 144 |
| 12 | Anti-tau scFvs Targeted to the Cytoplasm or Secretory Pathway Variably Modify Pathology and Neurodegenerative Phenotypes. Molecular Therapy, 2021, 29, 859-872. | 3.7 | 26 |
| 13 | Integrative functional genomic analysis of intron retention in human and mouse brain with Alzheimer's disease. Alzheimer's and Dementia, 2021, 17, 984-1004. | 0.4 | 25 |
| 14 | Precision therapeutic targets for COVID-19. Virology Journal, 2021, 18, 66. | 1.4 | 40 |
| 15 | Soluble Î±-synucleinâ€“antibody complexes activate the NLRP3 inflammasome in hiPSC-derived microglia. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, . | 3.3 | 69 |
| 16 | Modulating innate immune activation states impacts the efficacy of specific AÎ² immunotherapy. Molecular Neurodegeneration, 2021, 16, 32. | 4.4 | 4 |
| 17 | Microglia show differential transcriptomic response to AÎ² peptide aggregates ex vivo and in vivo. Life Science Alliance, 2021, 4, e202101108. | 1.3 | 17 |
| 18 | Photodynamic studies reveal rapid formation and appreciable turnover of tau inclusions. Acta Neuropathologica, 2021, 141, 359-381. | 3.9 | 13 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Diffusion magnetic resonance imaging-derived free water detects neurodegenerative pattern induced by interferon-Î³. Brain Structure and Function, 2020, 225, 427-439. | 1.2 | 31 |
| 20 | Intracerebral Expression of AAV-APOE4 Is Not Sufficient to Alter Tau Burden in Two Distinct Models of Tauopathy. Molecular Neurobiology, 2020, 57, 1986-2001. | 1.9 | 9 |
| 21 | Atlas of Transcription Factor Binding Sites from ENCODE DNase Hypersensitivity Data across 27 Tissue Types. Cell Reports, 2020, 32, 108029. | 2.9 | 28 |
| 22 | Metformin inhibits RAN translation through PKR pathway and mitigates disease in C9orf72 ALS/FTD mice. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 18591-18599. | 3.3 | 79 |
| 23 | Fyn depletion ameliorates tauP301L-induced neuropathology. Acta Neuropathologica Communications, 2020, 8, 108. | 2.4 | 17 |
| 24 | Meta-Analysis of the Alzheimerâ€™s Disease Human Brain Transcriptome and Functional Dissection in Mouse Models. Cell Reports, 2020, 32, 107908. | 2.9 | 199 |
| 25 | AÃŸ40 displays amyloidogenic properties in the non-transgenic mouse brain but does not exacerbate AÃŸ42 toxicity in Drosophila. Alzheimer's Research and Therapy, 2020, 12, 132. | 3.0 | 3 |
| 26 | Î³-Secretase modulators exhibit selectivity for modulation of APP cleavage but inverse Î³-secretase modulators do not. Alzheimer's Research and Therapy, 2020, 12, 61. | 3.0 | 6 |
| 27 | CD28 Signaling Drives Notch Ligand Expression on CD4 T Cells. Frontiers in Immunology, 2020, 11, 735. | 2.2 | 11 |
| 28 | Do infections have a role in the pathogenesis of Alzheimer disease?. Nature Reviews Neurology, 2020, 16, 193-197. | 4.9 | 96 |
| 29 | Utilizing minimally purified secreted rAAV for rapid and cost-effective manipulation of gene expression in the CNS. Molecular Neurodegeneration, 2020, 15, 15. | 4.4 | 9 |
| 30 | Large-scale proteomic analysis of Alzheimerâ€™s disease brain and cerebrospinal fluid reveals early changes in energy metabolism associated with microglia and astrocyte activation. Nature Medicine, 2020, 26, 769-780. | 15.2 | 547 |
| 31 | Diversity in AÎ² deposit morphology and secondary proteome insolubility across models of Alzheimer-typeÂamyloidosis. Acta Neuropathologica Communications, 2020, 8, 43. | 2.4 | 16 |
| 32 | A cognitive stress test for prodromal Alzheimer's disease: Multiethnic generalizability. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2019, 11, 550-559. | 1.2 | 16 |
| 33 | Combining P301L and S320F tau variants produces a novel accelerated model of tauopathy. Human Molecular Genetics, 2019, 28, 3255-3269. | 1.4 | 24 |
| 34 | Neurite orientation dispersion and density imaging reveals white matter and hippocampal microstructure changes produced by Interleukin-6 in the TgCRND8 mouse model of amyloidosis. NeuroImage, 2019, 202, 116138. | 2.1 | 34 |
| 35 | Intra- and extracellular Î²-amyloid overexpression via adeno-associated virus-mediated gene transfer impairs memory and synaptic plasticity in the hippocampus. Scientific Reports, 2019, 9, 15936. | 1.6 | 12 |
| 36 | Free-water imaging of the hippocampus is a sensitive marker of Alzheimer's disease. NeuroImage: Clinical, 2019, 24, 101985. | 1.4 | 35 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | Cardiac MLC2 kinase is localized to the Z-disc and interacts with Î±-actinin2. Scientific Reports, 2019, 9, 12580. | 1.6 | 7 |
| 38 | Individual and combined presenilin 1 and 2 knockouts reveal that both have highly overlapping functions in HEK293T cells. Journal of Biological Chemistry, 2019, 294, 11276-11285. | 1.6 | 15 |
| 39 | APP-Mediated Signaling Prevents Memory Decline in Alzheimerâ€™s Disease Mouse Model. Cell Reports, 2019, 27, 1345-1355.e6. | 2.9 | 20 |
| 40 | Harnessing Immunoproteostasis to Treat Neurodegenerative Disorders. Neuron, 2019, 101, 1003-1015. | 3.8 | 29 |
| 41 | Alzheimerâ€™s disease phospholipase C-gamma-2 (PLCG2) protective variant is a functional hypermorph. Alzheimer's Research and Therapy, 2019, 11, 16. | 3.0 | 100 |
| 42 | MAPT mutations, tauopathy, and mechanisms of neurodegeneration. Laboratory Investigation, 2019, 99, 912-928. | 1.7 | 190 |
| 43 | rAAV-based brain slice culture models of Alzheimerâ€™s and Parkinsonâ€™s disease inclusion pathologies. Journal of Experimental Medicine, 2019, 216, 539-555. | 4.2 | 48 |
| 44 | An anti-CRF antibody suppresses the HPA axis and reverses stress-induced phenotypes. Journal of Experimental Medicine, 2019, 216, 2479-2491. | 4.2 | 7 |
| 45 | Organotypic brain slice cultures to model neurodegenerative proteinopathies. Molecular Neurodegeneration, 2019, 14, 45. | 4.4 | 69 |
| 46 | Phosphorylation of serine 305 in tau inhibits aggregation. Neuroscience Letters, 2019, 692, 187-192. | 1.0 | 25 |
| 47 | ALS-Linked SOD1 Mutants Enhance Neurite Outgrowth and Branching in Adult Motor Neurons. IScience, 2019, 11, 294-304. | 1.9 | 28 |
| 48 | Integrative approach to sporadic Alzheimerâ€™s disease: deficiency of TYROBP in a tauopathy mouse model reduces C1q and normalizes clinical phenotype while increasing spread and state of phosphorylation of tau. Molecular Psychiatry, 2019, 24, 1383-1397. | 4.1 | 46 |
| 49 | Distinct differences in prion-like seeding and aggregation between Tau protein variants provide mechanistic insights into tauopathies. Journal of Biological Chemistry, 2018, 293, 2408-2421. | 1.6 | 103 |
| 50 | Increased brain hemopexin levels improve outcomes after intracerebral hemorrhage. Journal of Cerebral Blood Flow and Metabolism, 2018, 38, 1032-1046. | 2.4 | 31 |
| 51 | Ifngr1 and Stat1 mediated canonical Ifn-Î³ signaling drives nigrostriatal degeneration. Neurobiology of Disease, 2018, 110, 133-141. | 2.1 | 10 |
| 52 | Short AÎ² peptides attenuate AÎ²42 toxicity in vivo. Journal of Experimental Medicine, 2018, 215, 283-301. | 4.2 | 56 |
| 53 | Conserved brain myelination networks are altered in Alzheimer's and other neurodegenerative diseases. Alzheimer's and Dementia, 2018, 14, 352-366. | 0.4 | 116 |
| 54 | Notch Signaling Regulates Mitochondrial Metabolism and NF-ÎºB Activity in Triple-Negative Breast Cancer Cells via IKKÎ±-Dependent Non-canonical Pathways. Frontiers in Oncology, 2018, 8, 575. | 1.3 | 64 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | DDIS-06. AAV TOOLKIT ENABLING PRECISION COMBINATORIAL VIROTHERAPY FOR GLIOBLASTOMA. Neuro-Oncology, 2018, 20, vi70-vi70. | 0.6 | 0 |
| 56 | Alzheimer's disease: The right drug, the right time. Science, 2018, 362, 1250-1251. | 6.0 | 114 |
| 57 | Designing antibodies against LRRK2-targeted tau epitopes. PLoS ONE, 2018, 13, e0204367. | 1.1 | 1 |
| 58 | Animal models of neurodegenerative diseases. Nature Neuroscience, 2018, 21, 1370-1379. | 7.1 | 358 |
| 59 | Highâ€affinity interactions and signal transduction between AÎ² oligomers and <scp>TREM</scp> 2. EMBO Molecular Medicine, 2018, 10, . | 3.3 | 86 |
| 60 | Motor neuron loss and neuroinflammation in a model of Î±-synuclein-induced neurodegeneration. Neurobiology of Disease, 2018, 120, 98-106. | 2.1 | 32 |
| 61 | TLR5 decoy receptor as a novel anti-amyloid therapeutic for Alzheimerâ€™s disease. Journal of Experimental Medicine, 2018, 215, 2247-2264. | 4.2 | 50 |
| 62 | Notch1 primes CD4 T cells for T helper type I differentiation through its early effects on miR-29. Molecular Immunology, 2018, 99, 191-198. | 1.0 | 16 |
| 63 | Novel monoclonal antibodies targeting the microtubule-binding domain of human tau. PLoS ONE, 2018, 13, e0195211. | 1.1 | 12 |
| 64 | Notch Signaling in Myeloid Cells as a Regulator of Tumor Immune Responses. Frontiers in Immunology, 2018, 9, 1288. | 2.2 | 38 |
| 65 | Divergent brain gene expression patterns associate with distinct cell-specific tau neuropathology traits in progressive supranuclear palsy. Acta Neuropathologica, 2018, 136, 709-727. | 3.9 | 47 |
| 66 | Challenges in Passive Immunization Strategies to Treat Parkinson Disease. JAMA Neurology, 2018, 75, 1180. | 4.5 | 5 |
| 67 | Amyloid Î² peptides overexpression in retinal pigment epithelial cells via AAV-mediated gene transfer mimics AMD-like pathology in mice. Scientific Reports, 2017, 7, 3222. | 1.6 | 28 |
| 68 | Parkinson Disease and Autoimmune Disordersâ€”What Can We Learn From Genome-wide Pleiotropy?. JAMA Neurology, 2017, 74, 769. | 4.5 | 2 |
| 69 | Inflammatory pre-conditioning restricts the seeded induction of Î±-synuclein pathology in wild type mice. Molecular Neurodegeneration, 2017, 12, 1. | 4.4 | 104 |
| 70 | A candidate regulatory variant at the TREM gene cluster associates with decreased Alzheimer's disease risk and increased TREML1 and TREM2 brain gene expression. Alzheimer's and Dementia, 2017, 13, 663-673. | 0.4 | 48 |
| 71 | Î³â€Secretase inhibitors in cancer clinical trials are pharmacologically and functionally distinct. EMBO Molecular Medicine, 2017, 9, 950-966. | 3.3 | 123 |
| 72 | Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease. Nature Genetics, 2017, 49, 1373-1384. | 9.4 | 783 |

| # | Article | IF | Citations |
|---|---|---|---|
| 73 | Recovery from Proactive Semantic Interference and MRI Volume: AÂReplication and Extension Study. Journal of Alzheimer's Disease, 2017, 59, 131-139. | 1.2 | 27 |
| 74 | Intrastriatal injection of Î±-synuclein can lead to widespread synucleinopathy independent of neuroanatomic connectivity. Molecular Neurodegeneration, 2017, 12, 40. | 4.4 | 51 |
| 75 | Targeting psychologic stress signaling pathways in Alzheimerâ€™s disease. Molecular Neurodegeneration, 2017, 12, 49. | 4.4 | 47 |
| 76 | Proteolysis of Î±â€synuclein fibrils in the lysosomal pathway limits induction of inclusion pathology. Journal of Neurochemistry, 2017, 140, 662-678. | 2.1 | 59 |
| 77 | A KCNC3 mutation causes a neurodevelopmental, non-progressive SCA13 subtype associated with dominant negative effects and aberrant EGFR trafficking. PLoS ONE, 2017, 12, e0173565. | 1.1 | 22 |
| 78 | Linkage, whole genome sequence, and biological data implicate variants in RAB10 in Alzheimerâ€™s disease resilience. Genome Medicine, 2017, 9, 100. | 3.6 | 67 |
| 79 | Generation and characterization of new monoclonal antibodies targeting the PHF1 and AT8 epitopes on human tau. Acta Neuropathologica Communications, 2017, 5, 58. | 2.4 | 39 |
| 80 | A novel panel of Î±-synuclein antibodies reveal distinctive staining profiles in synucleinopathies. PLoS ONE, 2017, 12, e0184731. | 1.1 | 45 |
| 81 | Overcoming translational barriers impeding development of Alzheimer's disease modifying therapies. Journal of Neurochemistry, 2016, 139, 224-236. | 2.1 | 17 |
| 82 | Gene expression, methylation and neuropathology correlations at progressive supranuclear palsy risk loci. Acta Neuropathologica, 2016, 132, 197-211. | 3.9 | 49 |
| 83 | Holdase activity of secreted Hsp70 masks amyloid-Î²42 neurotoxicity in Drosophila. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E5212-21. | 3.3 | 60 |
| 84 | Host immune defence, amyloid-Î² peptide and Alzheimer disease. Nature Reviews Neurology, 2016, 12, 433-434. | 4.9 | 20 |
| 85 | Deficiency in either COX-1 or COX-2 genes does not affect amyloid beta protein burden in amyloid precursor protein transgenic mice. Biochemical and Biophysical Research Communications, 2016, 478, 286-292. | 1.0 | 7 |
| 86 | Microglia-specific targeting by novel capsid-modified AAV6 vectors. Molecular Therapy - Methods and Clinical Development, 2016, 3, 16026. | 1.8 | 91 |
| 87 | Cerebrospinal Biomarkers in Alzheimer Diseaseâ€”Potential Roles as Markers of Prognosis and Neuroplasticity. JAMA Neurology, 2016, 73, 508. | 4.5 | 3 |
| 88 | Non-prion-type transmission in A53T Î±-synuclein transgenic mice: a normal component of spinal homogenates from naÃ¯ve non-transgenic mice induces robust Î±-synuclein pathology. Acta Neuropathologica, 2016, 131, 151-154. | 3.9 | 19 |
| 89 | Viral expression of ALS-linked ubiquilin-2 mutants causes inclusion pathology and behavioral deficits in mice. Molecular Neurodegeneration, 2015, 10, 25. | 4.4 | 47 |
| 90 | Studies of lipopolysaccharide effects on the induction of Î±-synuclein pathology by exogenous fibrils in transgenic mice. Molecular Neurodegeneration, 2015, 10, 32. | 4.4 | 29 |

| # | Article | IF | Citations |
|---|---|---|---|
| 91 | Modulation of AÎ²42 in vivo by Î³-secretase modulator in primates and humans. Alzheimer's Research and Therapy, 2015, 7, 55. | 3.0 | 9 |
| 92 | p53 Modulates Notch Signaling in MCFâ€7 Breast Cancer Cells by Associating With the Notch Transcriptional Complex Via MAML1. Journal of Cellular Physiology, 2015, 230, 3115-3127. | 2.0 | 27 |
| 93 | Î³-Secretase Modulators and APH1 Isoforms Modulate Î³-Secretase Cleavage but Not Position of Îµ-Cleavage of the Amyloid Precursor Protein (APP). PLoS ONE, 2015, 10, e0144758. | 1.1 | 11 |
| 94 | Inefficient induction and spread of seeded tau pathology in P301L mouse model of tauopathy suggests inherent physiological barriers to transmission. Acta Neuropathologica, 2015, 130, 303-305. | 3.9 | 9 |
| 95 | Re-Opening the Critical Window for Estrogen Therapy. Journal of Neuroscience, 2015, 35, 16077-16093. | 1.7 | 47 |
| 96 | Increased free water in the substantia nigra of Parkinson's disease: a single-site and multi-site study. Neurobiology of Aging, 2015, 36, 1097-1104. | 1.5 | 133 |
| 97 | IL-10 Alters Immunoproteostasis in APP Mice, Increasing Plaque Burden and Worsening Cognitive Behavior. Neuron, 2015, 85, 519-533. | 3.8 | 292 |
| 98 | The stress response neuropeptide <scp>CRF</scp> increases amyloidâ€Î² production by regulating Î³â€secretase activity. EMBO Journal, 2015, 34, 1674-1686. | 3.5 | 47 |
| 99 | Widespread and Efficient Transduction of Spinal Cord and Brain Following Neonatal AAV Injection and Potential Disease Modifying Effect in ALS Mice. Molecular Therapy, 2015, 23, 53-62. | 3.7 | 50 |
| 100 | A Human Monoclonal IgG That Binds AÎ² Assemblies and Diverse Amyloids Exhibits Anti-Amyloid ActivitiesIn VitroandIn Vivo. Journal of Neuroscience, 2015, 35, 6265-6276. | 1.7 | 23 |
| 101 | Anti-AÎ² single-chain variable fragment antibodies exert synergistic neuroprotective activities inDrosophilamodels of Alzheimer's disease. Human Molecular Genetics, 2015, 24, 6093-6105. | 1.4 | 20 |
| 102 | IFNâ€Î³ promotes Ï„ phosphorylation without affecting mature tangles. FASEB Journal, 2015, 29, 4384-4398. | 0.2 | 23 |
| 103 | Differential Inhibition of Signal Peptide Peptidase Family Members by Established Î³-Secretase Inhibitors. PLoS ONE, 2015, 10, e0128619. | 1.1 | 15 |
| 104 | Independent Relationship between Amyloid Precursor Protein (APP) Dimerization and Î³-Secretase Processivity. PLoS ONE, 2014, 9, e111553. | 1.1 | 30 |
| 105 | Genetic Suppression of Transgenic APP Rescues Hypersynchronous Network Activity in a Mouse Model of Alzeimer's Disease. Journal of Neuroscience, 2014, 34, 3826-3840. | 1.7 | 144 |
| 106 | Î³-Secretase Processing and Effects of Î³-Secretase Inhibitors and Modulators on Long AÎ² Peptides in Cells. Journal of Biological Chemistry, 2014, 289, 3276-3287. | 1.6 | 22 |
| 107 | NOTCH1 Can Initiate NF-ÃŽÂºB Activation via Cytosolic Interactions with Components of the T Cell Signalosome. Frontiers in Immunology, 2014, 5, 249. | 2.2 | 47 |
| 108 | Non-Canonical Notch Signaling Drives Activation and Differentiation of Peripheral CD4+ T Cells. Frontiers in Immunology, 2014, 5, 54. | 2.2 | 75 |

| # | Article | IF | Citations |
|---|---|---|---|
| 109 | Divergent effects of the H50Q and G51D SNCA mutations on the aggregation of Î±â€synuclein. Journal of Neurochemistry, 2014, 131, 859-867. | 2.1 | 104 |
| 110 | Intracerebroventricular Viral Injection of the Neonatal Mouse Brain for Persistent and Widespread Neuronal Transduction. Journal of Visualized Experiments, 2014, , 51863. | 0.2 | 151 |
| 111 | Amyloidogenic Î±-synuclein seeds do not invariably induce rapid, widespread pathology in mice. Acta Neuropathologica, 2014, 127, 645-665. | 3.9 | 103 |
| 112 | Brain Injection of Î±-Synuclein Induces Multiple Proteinopathies, Gliosis, and a Neuronal Injury Marker. Journal of Neuroscience, 2014, 34, 12368-12378. | 1.7 | 115 |
| 113 | Open questions for Alzheimerâ€™s disease immunotherapy. Alzheimer's Research and Therapy, 2014, 6, 3. | 3.0 | 77 |
| 114 | Intramuscular injection of Î±-synuclein induces CNS Î±-synuclein pathology and a rapid-onset motor phenotype in transgenic mice. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 10732-10737. | 3.3 | 277 |
| 115 | The effect of brief neonatal cryoanesthesia on physical development and adult cognitive function in mice. Behavioural Brain Research, 2014, 259, 253-260. | 1.2 | 13 |
| 116 | O2-06-03: CAN WE TARGET CORTICOTROPIN RELEASING FACTOR (CRF) FOR THERAPEUTIC BENEFIT IN AD?. , 2014, 10, P175-P175. | | 0 |
| 117 | Differences in memory development among C57BL/6NCrl, 129S2/SvPasCrl, and FVB/NCrl mice after delay and trace fear conditioning. Comparative Medicine, 2014, 64, 4-12. | 0.4 | 11 |
| 118 | Normal cognition in transgenic BRI2-AÎ² mice. Molecular Neurodegeneration, 2013, 8, 15. | 4.4 | 74 |
| 119 | Conformational templating of Î±-synuclein aggregates in neuronal-glial cultures. Molecular Neurodegeneration, 2013, 8, 17. | 4.4 | 61 |
| 120 | Induction of CNS Î±-synuclein pathology by fibrillar and non-amyloidogenic recombinant Î±-synuclein. Acta Neuropathologica Communications, 2013, 1, 38. | 2.4 | 78 |
| 121 | Robust cytoplasmic accumulation of phosphorylated TDP-43 in transgenic models of tauopathy. Acta Neuropathologica, 2013, 126, 39-50. | 3.9 | 24 |
| 122 | Viral transduction of the neonatal brain delivers controllable genetic mosaicism for visualising and manipulating neuronal circuits in vivo. European Journal of Neuroscience, 2013, 37, 1203-1220. | 1.2 | 123 |
| 123 | Biomarkers for Alzheimer's disease in plasma, serum and blood - conceptual and practical problems. Alzheimer's Research and Therapy, 2013, 5, 10. | 3.0 | 51 |
| 124 | Anti-Tau Antibodies: Hitting the Target. Neuron, 2013, 80, 254-256. | 3.8 | 16 |
| 125 | S1-01-04: Cholesterol metabolites as endogenous gamma-secretase modulators. , 2013, 9, P121-P122. | | 0 |
| 126 | Unbiased screen reveals ubiquilin-1 and -2 highly associated with huntingtin inclusions. Brain Research, 2013, 1524, 62-73. | 1.1 | 38 |

| # | Article | IF | Citations |
|---|---|---|---|
| 127 | The Influence of 5-Lipoxygenase on Alzheimerâ€™s Disease-Related Tau Pathology: In Vivo and In Vitro Evidence. Biological Psychiatry, 2013, 74, 321-328. | 0.7 | 26 |
| 128 | Reversible Pathologic and Cognitive Phenotypes in an Inducible Model of Alzheimer-Amyloidosis. Journal of Neuroscience, 2013, 33, 3765-3779. | 1.7 | 46 |
| 129 | Progress in Alzheimer's disease research circa 2013: Is the glass half empty or half full?. Alzheimer's Research and Therapy, 2013, 5, 26. | 3.0 | 1 |
| 130 | Alzheimer's disease risk alleles in TREM2 illuminate innate immunity in Alzheimer's disease. Alzheimer's Research and Therapy, 2013, 5, 24. | 3.0 | 33 |
| 131 | Î³-Secretase inhibitors and modulators. Biochimica Et Biophysica Acta - Biomembranes, 2013, 1828, 2898-2907. | 1.4 | 238 |
| 132 | Steroids as Î³â€secretase modulators. FASEB Journal, 2013, 27, 3775-3785. | 0.2 | 33 |
| 133 | Therapeutic targeting of NOTCH signaling ameliorates immune-mediated bone marrow failure of aplastic anemia. Journal of Experimental Medicine, 2013, 210, 1311-1329. | 4.2 | 67 |
| 134 | Accelerated neurodegeneration through chaperone-mediated oligomerization of tau. Journal of Clinical Investigation, 2013, 123, 4158-4169. | 3.9 | 246 |
| 135 | Capsid Serotype and Timing of Injection Determines AAV Transduction in the Neonatal Mice Brain. PLoS ONE, 2013, 8, e67680. | 1.1 | 149 |
| 136 | Thinking laterally about neurodegenerative proteinopathies. Journal of Clinical Investigation, 2013, 123, 1847-1855. | 3.9 | 98 |
| 137 | Shifting a complex debate onÎ³-secretase cleavage and Alzheimer's disease. EMBO Journal, 2012, 31, 2237-2239. | 3.5 | 7 |
| 138 | Targeting the ERAD pathway via inhibition of signal peptide peptidase for antiparasitic therapeutic design. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 21486-21491. | 3.3 | 89 |
| 139 | Alzheimer's Î²-Secretase (BACE1) Regulates the cAMP/PKA/CREB Pathway Independently of Î²-Amyloid. Journal of Neuroscience, 2012, 32, 11390-11395. | 1.7 | 104 |
| 140 | Retention in Endoplasmic Reticulum 1 (RER1) Modulates Amyloid-Î² (AÎ²) Production by Altering Trafficking of Î³-Secretase and Amyloid Precursor Protein (APP). Journal of Biological Chemistry, 2012, 287, 40629-40640. | 1.6 | 29 |
| 141 | Î²â€Secretase (BACE1) inhibition causes retinal pathology by vascular dysregulation and accumulation of age pigment. EMBO Molecular Medicine, 2012, 4, 980-991. | 3.3 | 125 |
| 142 | Adeno-associated virus-mediated brain delivery of 5-lipoxygenase modulates the AD-like phenotype of APP mice. Molecular Neurodegeneration, 2012, 7, 1. | 4.4 | 96 |
| 143 | Notch signals in the endothelium and cancer "stem-like" cells: opportunities for cancer therapy. Vascular Cell, 2012, 4, 7. | 0.2 | 74 |
| 144 | Cyanobacterial Peptides as a Prototype for the Design of Potent Î²-Secretase Inhibitors and the Development of Selective Chemical Probes for Other Aspartic Proteases. Journal of Medicinal Chemistry, 2012, 55, 10749-10765. | 2.9 | 42 |

| # | Article | IF | Citations |
|---|---|---|---|
| 145 | Expression of Fused in sarcoma mutations in mice recapitulates the neuropathology of FUS proteinopathies and provides insight into disease pathogenesis. Molecular Neurodegeneration, 2012, 7, 53. | 4.4 | 61 |
| 146 | Transient pharmacologic lowering of AÎ² production prior to deposition results in sustained reduction of amyloid plaque pathology. Molecular Neurodegeneration, 2012, 7, 39. | 4.4 | 29 |
| 147 | Hippocampal expression of murine IL-4 results in exacerbation of amyloid deposition. Molecular Neurodegeneration, 2012, 7, 36. | 4.4 | 98 |
| 148 | Age-related increase in amyloid plaque burden is associated with impairment in conditioned fear memory in CRND8 mouse model of amyloidosis. Alzheimer's Research and Therapy, 2012, 4, 21. | 3.0 | 29 |
| 149 | Overlapping profiles of Abeta peptides in the Alzheimer's disease and pathological aging brains. Alzheimer's Research and Therapy, 2012, 4, 18. | 3.0 | 92 |
| 150 | Recent Alzheimer's disease research highlights. Alzheimer's Research and Therapy, 2012, 4, 14. | 3.0 | 0 |
| 151 | Analysis of Proteolytic Processes and Enzymatic Activities in the Generation of Huntingtin N-Terminal Fragments in an HEK293 Cell Model. PLoS ONE, 2012, 7, e50750. | 1.1 | 22 |
| 152 | Right sizing funding for Alzheimer's disease. Alzheimer's Research and Therapy, 2011, 3, 17. | 3.0 | 2 |
| 153 | Anti-AÎ² Therapeutics in Alzheimer's Disease: The Need for a Paradigm Shift. Neuron, 2011, 69, 203-213. | 3.8 | 350 |
| 154 | Hippocampal expression of murine TNFÎ± results in attenuation of amyloid deposition in vivo. Molecular Neurodegeneration, 2011, 6, 16. | 4.4 | 106 |
| 155 | Substrate Sequence Influences Î³-Secretase Modulator Activity, Role of the Transmembrane Domain of the Amyloid Precursor Protein. Journal of Biological Chemistry, 2011, 286, 39794-39803. | 1.6 | 31 |
| 156 | Robust Amyloid Clearance in a Mouse Model of Alzheimer's Disease Provides Novel Insights into the Mechanism of Amyloid-Î² Immunotherapy. Journal of Neuroscience, 2011, 31, 4124-4136. | 1.7 | 97 |
| 157 | Lysine 624 of the Amyloid Precursor Protein (APP) Is a Critical Determinant of Amyloid Î² Peptide Length. Journal of Biological Chemistry, 2011, 286, 39804-39812. | 1.6 | 61 |
| 158 | Interferon-Î³ induces progressive nigrostriatal degeneration and basal ganglia calcification. Nature Neuroscience, 2011, 14, 694-696. | 7.1 | 67 |
| 159 | Anesthetic Propofol Attenuates the Isoflurane-Induced Caspase-3 Activation and AÎ² Oligomerization. PLoS ONE, 2011, 6, e27019. | 1.1 | 56 |
| 160 | Adeno-Associated Virus-Mediated Rescue of the Cognitive Defects in a Mouse Model for Angelman Syndrome. PLoS ONE, 2011, 6, e27221. | 1.1 | 92 |
| 161 | Convection-enhanced delivery and systemic mannitol increase gene product distribution of AAV vectors 5, 8, and 9 and increase gene product in the adult mouse brain. Journal of Neuroscience Methods, 2010, 194, 144-153. | 1.3 | 61 |
| 162 | IFN-Î³ Promotes Complement Expression and Attenuates Amyloid Plaque Deposition in Amyloid Î² Precursor Protein Transgenic Mice. Journal of Immunology, 2010, 184, 5333-5343. | 0.4 | 169 |

| # | Article | IF | Citations |
|---|---|---|---|
| 163 | Phosphorylation Dynamics Regulate Hsp27-Mediated Rescue of Neuronal Plasticity Deficits in Tau Transgenic Mice. Journal of Neuroscience, 2010, 30, 15374-15382. | 1.7 | 105 |
| 164 | Massive gliosis induced by interleukinâ€6 suppresses AÎ² deposition in vivo: evidence against inflammation as a driving force for amyloid deposition. FASEB Journal, 2010, 24, 548-559. | 0.2 | 278 |
| 165 | Reduced Alzheimer's Disease Î²-Amyloid Deposition in Transgenic Mice ExpressingS-Palmitoylation-Deficient APH1aL and Nicastrin. Journal of Neuroscience, 2010, 30, 16160-16169. | 1.7 | 37 |
| 166 | Sorting Out Frontotemporal Dementia?. Neuron, 2010, 68, 601-603. | 3.8 | 6 |
| 167 | Targeting AÎ² and tau in Alzheimer's disease, an early interim report. Experimental Neurology, 2010, 223, 252-266. | 2.0 | 80 |
| 168 | The secretases: enzymes with therapeutic potential in Alzheimer disease. Nature Reviews Neurology, 2010, 6, 99-107. | 4.9 | 702 |
| 169 | Targeting Notch to Target Cancer Stem Cells. Clinical Cancer Research, 2010, 16, 3141-3152. | 3.2 | 410 |
| 170 | Inhibition of Notch signaling reduces the stem-like population of breast cancer cells and prevents mammosphere formation. Anticancer Research, 2010, 30, 3853-67. | 0.5 | 115 |
| 171 | A Small Molecule Inhibitor of Signal Peptide Peptidase Inhibits Plasmodium Development in the Liver and Decreases Malaria Severity. PLoS ONE, 2009, 4, e5078. | 1.1 | 27 |
| 172 | Notch Regulates Cytolytic Effector Function in CD8+ T Cells. Journal of Immunology, 2009, 182, 3380-3389. | 0.4 | 150 |
| 173 | Identification of Ligand-Induced Proteolytic Cleavage and Ectodomain Shedding of VEGFR-1/FLT1 in Leukemic Cancer Cells. Cancer Research, 2009, 69, 2607-2614. | 0.4 | 67 |
| 174 | Avoiding Unintended Toxicity. Science, 2009, 324, 603-604. | 6.0 | 8 |
| 175 | Inhibition of soluble TNF signaling in a mouse model of Alzheimer's disease prevents pre-plaque amyloid-associated neuropathology. Neurobiology of Disease, 2009, 34, 163-177. | 2.1 | 236 |
| 176 | "What kills neurons in neurodegenerative diseases?", a review series in an open access journal. Molecular Neurodegeneration, 2009, 4, 7. | 4.4 | 4 |
| 177 | The therapeutic importance of understanding mechanisms of neuronal cell death in neurodegenerative disease. Molecular Neurodegeneration, 2009, 4, 8. | 4.4 | 52 |
| 178 | Suppression of hippocampal TRPM7 protein prevents delayed neuronal death in brain ischemia. Nature Neuroscience, 2009, 12, 1300-1307. | 7.1 | 259 |
| 179 | Signal peptide peptidases: A family of intramembrane-cleaving proteases that cleave type 2 transmembrane proteins. Seminars in Cell and Developmental Biology, 2009, 20, 225-230. | 2.3 | 59 |
| 180 | Proteinopathy-induced neuronal senescence: a hypothesis for brain failure in Alzheimer's and other neurodegenerative diseases. Alzheimer's Research and Therapy, 2009, 1, 5. | 3.0 | 77 |

| # | Article | IF | Citations |
|---|---|---|---|
| 181 | Welcome to Alzheimer's Research & Therapy. Alzheimer's Research and Therapy, 2009, 1, 1. | 3.0 | 6 |
| 182 | Aberrant cleavage of TDP-43 enhances aggregation and cellular toxicity. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 7607-7612. | 3.3 | 523 |
| 183 | Generating Differentially Targeted Amyloid-Î² Specific Intrabodies as a Passive Vaccination Strategy for Alzheimer's Disease. Molecular Therapy, 2009, 17, 2031-2040. | 3.7 | 43 |
| 184 | Notch signaling mediates G1/S cell-cycle progression in T cells via cyclin D3 and its dependent kinases. Blood, 2009, 113, 1689-1698. | 0.6 | 173 |
| 185 | Notch signaling is activated by TLR stimulation and regulates macrophage functions. European Journal of Immunology, 2008, 38, 174-183. | 1.6 | 207 |
| 186 | Off the beaten pathway: the complex cross talk between Notch and NF-ÎºB. Laboratory Investigation, 2008, 88, 11-17. | 1.7 | 208 |
| 187 | Substrate-targeting Î³-secretase modulators. Nature, 2008, 453, 925-929. | 13.7 | 277 |
| 188 | BRI2 (ITM2b) Inhibits AÂ Deposition In Vivo. Journal of Neuroscience, 2008, 28, 6030-6036. | 1.7 | 110 |
| 189 | Independent Generation of AÎ²42 and AÎ²38 Peptide Species by Î³-Secretase. Journal of Biological Chemistry, 2008, 283, 17049-17054. | 1.6 | 70 |
| 190 | Transthyretin protects Alzheimer's mice from the behavioral and biochemical effects of AÎ² toxicity. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 2681-2686. | 3.3 | 245 |
| 191 | A Î³-secretase inhibitor and quinacrine reduce prions and prevent dendritic degeneration in murine brains. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 10595-10600. | 3.3 | 42 |
| 192 | Possible Mechanisms of Action of NSAIDs and Related Compounds that Modulate γ -Secretase Cleavage. Current Topics in Medicinal Chemistry, 2008, 8, 47-53. | 1.0 | 43 |
| 193 | Using leucine zipper to facilitate Î±â€synuclein assembly. FASEB Journal, 2008, 22, 3165-3174. | 0.2 | 10 |
| 194 | AÂ40 Inhibits Amyloid Deposition In Vivo. Journal of Neuroscience, 2007, 27, 627-633. | 1.7 | 327 |
| 195 | Epidermal Growth Factor Receptor and Notch Pathways Participate in the Tumor Suppressor Function of Î³-Secretase. Journal of Biological Chemistry, 2007, 282, 32264-32273. | 1.6 | 82 |
| 196 | Notch inhibition in Kaposi's sarcoma tumor cells leads to mitotic catastrophe through nuclear factor-ÎºB signaling. Molecular Cancer Therapeutics, 2007, 6, 1983-1992. | 1.9 | 36 |
| 197 | Statins Reduce Amyloid-Î² Production through Inhibition of Protein Isoprenylation. Journal of Biological Chemistry, 2007, 282, 26832-26844. | 1.6 | 156 |
| 198 | A multigram chemical synthesis of the Î³-secretase inhibitor LY411575 and its diastereoisomers. Bioorganic and Medicinal Chemistry Letters, 2007, 17, 6392-6395. | 1.0 | 64 |

| # | Article | IF | Citations |
|---|---|---|---|
| 199 | Novel rat Alzheimer's disease models based on AAV-mediated gene transfer to selectively increase hippocampal Aî² levels. Molecular Neurodegeneration, 2007, 2, 11. | 4.4 | 61 |
| 200 | Betaâ€secretase regulation in aging and disease. FASEB Journal, 2007, 21, A278. | 0.2 | 0 |
| 201 | Detection of presenilin-1 homodimer formation in intact cells using fluorescent lifetime imaging microscopy. Biochemical and Biophysical Research Communications, 2006, 340, 668-674. | 1.0 | 24 |
| 202 | Matrix metalloproteinase-9 contributes to brain extravasation and edema in fulminant hepatic failure mice. Journal of Hepatology, 2006, 44, 1105-1114. | 1.8 | 104 |
| 203 | Dysfunction of TGF-Î² signaling in Alzheimerâ€™s disease. Journal of Clinical Investigation, 2006, 116, 2855-2857. | 3.9 | 57 |
| 204 | Zoom in on neurodegeneration. Molecular Neurodegeneration, 2006, 1, 1. | 4.4 | 12 |
| 205 | C-terminal PAL motif of presenilin and presenilin homologues required for normal active site conformation. Journal of Neurochemistry, 2006, 96, 218-227. | 2.1 | 87 |
| 206 | Inhibitors of Rho-kinase modulate amyloid-Î² (AÎ²) secretion but lack selectivity for AÎ²42. Journal of Neurochemistry, 2006, 96, 355-365. | 2.1 | 37 |
| 207 | Disease modifying therapy for AD?. Journal of Neurochemistry, 2006, 99, 689-707. | 2.1 | 115 |
| 208 | Notch1 augments NF-ÎºB activity by facilitating its nuclear retention. EMBO Journal, 2006, 25, 129-138. | 3.5 | 271 |
| 209 | Frontotemporal dementia and parkinsonism associated with the IVS1+1G->A mutation in progranulin: a clinicopathologic study. Brain, 2006, 129, 3103-3114. | 3.7 | 105 |
| 210 | Filling the Gaps in the Aβ Cascade Hypothesis of Alzheimers Disease. Current Alzheimer Research, 2006, 3, 421-430. | 0.7 | 116 |
| 211 | Notch Signaling in Cancer. Current Molecular Medicine, 2006, 6, 905-918. | 0.6 | 219 |
| 212 | Intracranial Adeno-Associated Virus-Mediated Delivery of Anti-Pan Amyloid beta, Amyloid beta40, and Amyloid beta42 Single-Chain Variable Fragments Attenuates Plaque Pathology in Amyloid Precursor Protein Mice. Journal of Neuroscience, 2006, 26, 11923-11928. | 1.7 | 119 |
| 213 | Insights into the mechanisms of action of antiâ€Aî² antibodies in Alzheimer's disease mouse models. FASEB Journal, 2006, 20, 2576-2578. | 0.2 | 110 |
| 214 | Intramembrane proteolytic cleavage by human signal peptide peptidase like 3 and malaria signal peptide peptidase. FASEB Journal, 2006, 20, 1671-1679. | 0.2 | 42 |
| 215 | Efficient Neuronal Gene Transfer with AAV8 Leads to Neurotoxic Levels of Tau or Green Fluorescent Proteins. Molecular Therapy, 2006, 13, 517-527. | 3.7 | 180 |
| 216 | Bringing amyloid into focus. Nature Biotechnology, 2005, 23, 552-554. | 9.4 | 7 |

| # | Article | IF | Citations |
|---|---|---|---|
| 217 | Diverse compounds mimic Alzheimer diseaseâ€“causing mutations by augmenting AÎ²42 production. Nature Medicine, 2005, 11, 545-550. | 15.2 | 276 |
| 218 | Gamma secretase inhibitor blocks Notch activation and induces apoptosis in Kaposi's sarcoma tumor cells. Oncogene, 2005, 24, 6333-6344. | 2.6 | 195 |
| 219 | Inhibitors of Î³-secretase block in vivo and in vitro T helper type 1 polarization by preventing Notch upregulation of Tbx21. Nature Immunology, 2005, 6, 680-688. | 7.0 | 252 |
| 220 | Homing in on Intracellular AÎ²?. Neuron, 2005, 45, 639-642. | 3.8 | 24 |
| 221 | AÎ²42 Is Essential for Parenchymal and Vascular Amyloid Deposition in Mice. Neuron, 2005, 47, 191-199. | 3.8 | 524 |
| 222 | The AÎ² Hypothesis: Leading Us to Rationally-Designed Therapeutic Strategies for the Treatment or Prevention of Alzheimer Disease. Brain Pathology, 2005, 15, 84-87. | 2.1 | 91 |
| 223 | Anti-AÂ42- and anti-AÂ40-specific mAbs attenuate amyloid deposition in an Alzheimer disease mouse model. Journal of Clinical Investigation, 2005, 116, 193-201. | 3.9 | 172 |
| 224 | Inhibitors of gamma-secretase block in vivo and in vitro T helper type 1 polarization by preventing Notch upregulation of Tbx21. Nature Immunology, 2005, 6, 680-8. | 7.0 | 139 |
| 225 | A Signal Peptide Peptidase (SPP) Reporter Activity Assay Based on the Cleavage of Type II Membrane Protein Substrates Provides Further Evidence for an Inverted Orientation of the SPP Active Site Relative to Presenilin. Journal of Biological Chemistry, 2004, 279, 43148-43156. | 1.6 | 49 |
| 226 | Signal Peptide Peptidase Forms a Homodimer That Is Labeled by an Active Site-directed Î³-Secretase Inhibitor. Journal of Biological Chemistry, 2004, 279, 15153-15160. | 1.6 | 77 |
| 227 | P-346 Anti-A1â€“16, AÎ²35â€“40 and AÎ²35â€“42 single-chain variable region fragments as potential therapeutic agents for AD. Neurobiology of Aging, 2004, 25, S573. | 1.5 | 0 |
| 228 | Presenilin regulates capacitative calcium entry dependently and independently of Î³-secretase activity. Biochemical and Biophysical Research Communications, 2004, 322, 1145-1152. | 1.0 | 33 |
| 229 | Evidence That Nonsteroidal Anti-inflammatory Drugs Decrease Amyloid Î²42 Production by Direct Modulation of Î³-Secretase Activity. Journal of Biological Chemistry, 2003, 278, 31831-31837. | 1.6 | 259 |
| 230 | NSAIDs and enantiomers of flurbiprofen target Î³-secretase and lower AÎ²42 in vivo. Journal of Clinical Investigation, 2003, 112, 440-449. | 3.9 | 476 |
| 231 | Peptide-based, irreversible inhibitors of Î³-secretase activity. Biochemical and Biophysical Research Communications, 2003, 305, 529-533. | 1.0 | 3 |
| 232 | Immune responses against AÎ²1â€“42 in HLA class II transgenic mice: implications for AÎ²1â€“42 immune-mediated therapies. Neurobiology of Aging, 2003, 24, 969-976. | 1.5 | 32 |
| 233 | Triple-Transgenic Model of Alzheimer's Disease with Plaques and Tangles. Neuron, 2003, 39, 409-421. | 3.8 | 3,609 |
| 234 | TCR-Mediated Notch Signaling Regulates Proliferation and IFN-Î³ Production in Peripheral T Cells. Journal of Immunology, 2003, 171, 3019-3024. | 0.4 | 227 |

| # | Article | IF | Citations |
|---|---|---|---|
| 235 | Overexpression of nicastrin increases AÃŸ production. FASEB Journal, 2003, 17, 1138-1140. | 0.2 | 35 |
| 236 | AÎ²42-lowering Nonsteroidal Anti-inflammatory Drugs Preserve Intramembrane Cleavage of the Amyloid Precursor Protein (APP) and ErbB-4 Receptor and Signaling through the APP Intracellular Domain. Journal of Biological Chemistry, 2003, 278, 30748-30754. | 1.6 | 119 |
| 237 | The Non-cyclooxygenase Targets of Non-steroidal Anti-inflammatory Drugs, Lipoxygenases, Peroxisome Proliferator-activated Receptor, Inhibitor of Î°B Kinase, and NFÎºB, Do Not Reduce Amyloid Î²42 Production. Journal of Biological Chemistry, 2003, 278, 31825-31830. | 1.6 | 71 |
| 238 | Physiologic and Pathologic Events Mediated by Intramembranous and Juxtamembranous Proteolysis. Science Signaling, 2003, 2003, re4-re4. | 1.6 | 31 |
| 239 | Amyloid-Î² Immunization Effectively Reduces Amyloid Deposition in FcRÎ³<sup>-/-</sup>Knock-Out Mice. Journal of Neuroscience, 2003, 23, 8532-8538. | 1.7 | 205 |
| 240 | Alzheimer disease therapy: Can the amyloid cascade be halted?. Journal of Clinical Investigation, 2003, 111, 11-18. | 3.9 | 125 |
| 241 | Alzheimer disease therapy: Can the amyloid cascade be halted?. Journal of Clinical Investigation, 2003, 111, 11-18. | 3.9 | 57 |
| 242 | A physiologic signaling role for the Â-secretase-derived intracellular fragment of APP. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 4697-4702. | 3.3 | 261 |
| 243 | Inclusion body myositis-like phenotype induced by transgenic overexpression of ÂAPP in skeletal muscle. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 6334-6339. | 3.3 | 103 |
| 244 | Identification of a novel family of presenilin homologues. Human Molecular Genetics, 2002, 11, 1037-1044. | 1.4 | 157 |
| 245 | Cholesterol-Dependent Î³-Secretase Activity in Buoyant Cholesterol-Rich Membrane Microdomains. Neurobiology of Disease, 2002, 9, 11-23. | 2.1 | 406 |
| 246 | A Presenilin 1 Mutation Associated with Familial Frontotemporal Dementia Inhibits Î³-Secretase Cleavage of APP and Notch. Neurobiology of Disease, 2002, 9, 269-273. | 2.1 | 92 |
| 247 | Nonsteroidal antiinflammatory drugs as therapeutic agents for Alzheimer's disease. Drug Development Research, 2002, 56, 415-420. | 1.4 | 4 |
| 248 | Inflammation takes on Alzheimer disease. Nature Medicine, 2002, 8, 936-938. | 15.2 | 46 |
| 249 | gamma -Secretase Cleavage and Nuclear Localization of ErbB-4 Receptor Tyrosine Kinase. Science, 2001, 294, 2179-2181. | 6.0 | 825 |
| 250 | Reduced effectiveness of AÎ²1-42 immunization in APP transgenic mice with significant amyloid deposition. Neurobiology of Aging, 2001, 22, 721-727. | 1.5 | 148 |
| 251 | Î²-Secretase cleavage of the amyloid precursor protein mediates neuronal apoptosis caused by familial Alzheimerâ€™s disease mutations. Molecular Brain Research, 2001, 97, 103-113. | 2.5 | 59 |
| 252 | A subset of NSAIDs lower amyloidogenic AÎ²42 independently of cyclooxygenase activity. Nature, 2001, 414, 212-216. | 13.7 | 1,352 |

| # | Article | IF | Citations |
|---|---|---|---|
| 253 | Cholesterol modulation as an emerging strategy for the treatment of Alzheimer's disease. Drug Discovery Today, 2001, 6, 1049-1055. | 3.2 | 63 |
| 254 | Presenilin 1 Regulates Î²-Catenin-mediated Transcription in a Glycogen Synthase Kinase-3-independent Fashion. Journal of Biological Chemistry, 2001, 276, 38563-38569. | 1.6 | 35 |
| 255 | A Novel Î³-Secretase Assay Based on Detection of the Putative C-terminal Fragment-Î³ of Amyloid Î² Protein Precursor. Journal of Biological Chemistry, 2001, 276, 481-487. | 1.6 | 135 |
| 256 | Presenilin 1 Regulates Pharmacologically Distinct Î³-Secretase Activities. Journal of Biological Chemistry, 2000, 275, 26277-26284. | 1.6 | 93 |
| 257 | Cellâ€free assays for Î³â€secretase activity. FASEB Journal, 2000, 14, 2383-2386. | 0.2 | 108 |
| 258 | The Presenilin 1 C92S Mutation Increases AÎ² 42 Production. Biochemical and Biophysical Research Communications, 2000, 277, 261-263. | 1.0 | 19 |
| 259 | Biochemical detection of AÎ² isoforms: implications for pathogenesis, diagnosis, and treatment of Alzheimerâ€™s disease. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2000, 1502, 172-187. | 1.8 | 272 |
| 260 | Characterization by radiosequencing of the carboxyl-terminal derivatives produced from normal and mutant amyloid Î² protein precursors. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 1994, 1, 30-38. | 1.4 | 21 |
| 261 | Production of Amyloid Î² Protein from Normal Amyloid Î²-Protein Precursor (Î²APP) and the Mutated Î²APPS Linked to Familial Alzheimer's Diseasea. Annals of the New York Academy of Sciences, 1993, 695, 103-108. | 1.8 | 33 |
| 262 | Normal Processing of the Alzheimer's Disease Amyloid ? Protein Precursor Generates Potentially Amyloidogenic Carboxyl-Terminal Derivatives. Annals of the New York Academy of Sciences, 1992, 674, 138-148. | 1.8 | 27 |
| 263 | Secretory processing of the Alzheimer amyloid Î²A4 protein precursor is increased by protein phosphorylation. Biochemical and Biophysical Research Communications, 1992, 187, 1285-1290. | 1.0 | 115 |
| 264 | Expression of Î² amyloid protein precursor mRNAs: Recognition of a novel alternatively spliced form and quantitation in alzheimer's disease using PCR. Neuron, 1990, 4, 253-267. | 3.8 | 441 |